Scilex Holding Company(SCLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -49.8 | Insider Own | 11.67% | Shs Outstand | 7.0M | Perf Week | -5.61% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.2M | Perf Month | -24.74% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | - | Inst Own | 9.99% | Short Float | 2.46% | Perf Quarter | -7.83% |
| Income | -0.45B | P/S | 1.12 | EPS this Y | - | Inst Trans | -2.95% | Short Ratio | 1.33 | Perf Half Y | -12.13% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -265.83% | Short Interest | 0.15M | Perf YTD | -33.52% |
| Book/sh | -43.83 | P/C | 61.25 | EPS past 3/5Y | -81.59% -392.41% | ROE | - | 52W High | -76.33% ($21.34) | Perf Year | -68.1% |
| Cash/sh | 0.08 | P/FCF | 9.58 | Sales past 3/5Y | -7.35% - | ROIC | - | 52W Low | 93.11% ($2.62) | Perf 3Y | -90.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -310.88% | Gross Margin | 29.18% | Volatility(W/M) | 5.35% 6.31% | Perf 5Y | -97.69% |
| Dividend TTM | - | EV/Sales | 4.39 | Sales Y/Y TTM | -28.55% | Oper. Margin | -903.52% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.06 | EPS Q/Q | -124.28% | Profit Margin | -1418.45% | RSI (14) | 28.64 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.07 | Sales Q/Q | -22.78% | SMA20 | -11.33% ($5.7) | Beta | 1.68 | Target Price | $392.26 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -26.64% ($6.88) | Rel Volume | 0.18 | Prev Close | $5.2 |
| Employees | 34 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -21.6% ($6.44) | Avg Volume(3M) | 0.11M | Price | $5.05 |
| IPO | 2021/3/5 | Option/Short | No/Yes | Trades | 267 | Volume | 20,600 | Change | -2.88% |
Company
SCLX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is a US pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. Its commercialized products include ZTlido, a topical patch used for postherpetic neuralgia; ELYXYB, an oral solution for the acute treatment of migraines; and GLOPERBA, an oral colchicine for the prevention of gout, all of which expand non-opioid alternatives to narcotic painkillers.
Over the past 1 year, on the lower side
76% below its 1-year high.
SCLX has weak earning power
-903.52% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -90.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 10.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAU 0.00%
HDG 0.00%
ITOT 0.00%
URTY 0.00%It ranks #4 in the industry
Based on market cap of $36M.
SCLX $36M PER -
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is SCLX?
SCLX belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of SCLX?
The market cap of SCLX is approximately $36M, ranking 5,087 within its sector.
What is the 52-week high and low for SCLX?
SCLX has recorded a 52-week high of $21.34 and a low of $2.62.
